Approved
consistent with the understanding that any changes made as a result
of the pretest must be submitted for review and approval prior to
fielding the main study.
Inventory as of this Action
Requested
Previously Approved
06/30/2020
36 Months From Approved
3,441
0
0
530
0
0
0
0
0
This study will examine the effect of
the presence, language, and prominence of a disclosure
communicating information related to a prescription drug’s
accelerated approval in direct-to-consumer promotional materials.
We plan to conduct one pretest (N = 385) and one main study (N =
633) not longer than 20 minutes, administered via Internet panel.
We will vary the presence and prominence of the disclosure (e.g.,
varying the presence, size, color, and location of the disclosure)
on a website for a fictitious prescription drug. Participants will
view the website and then answer questions about the drug
information, including the disclosure.
Ila Mizrachi 301 796-7726
ila.mizrachi@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.